Karuna Therapeutics, Inc.
KRTX · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 5.53 | -0.90 | -1.74 | -1.63 |
| FCF Yield | -0.94% | -1.74% | -0.80% | -1.60% |
| EV / EBITDA | -91.29 | -45.54 | -65.80 | -52.84 |
| Quality | ||||
| ROIC | -10.26% | -10.18% | -8.35% | -6.44% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.98 | 0.92 | 0.62 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -73.94% | 1,810,129.82% | 1,818,332.01% | 2,243,321.11% |
| Free Cash Flow Growth | -1.11% | -70.43% | 35.95% | -28.21% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | 1.24 | 2.07 | 5.12 |
| Interest Coverage | -11.28 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.06 | 0.00 | 0.00 |
| Cash Conversion Cycle | 5,244.56 | 895.28 | -211.47 | -131.01 |